FP11 Circulating immunoregulatory B- and T-cell profiles in patients with melanoma modulated with checkpoint inhibitor immunotherapy
Clicks: 2
ID: 318407
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #267 of 313 articles by views in the british journal of dermatology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 313 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Introduction and aims We conducted deep immunophenotyping of circulating B- and T-cell repertoires of patients with melanoma at baseline and longitudinally during checkpoint inhibitor (CPI) immunotherapy to assess phenotypic changes and to identify predictive biomarkers of response. Methods A 45-marker mass cytometry panel was utilized to profile circulating adaptive immune features in patients and healthy participants. Paired pretreatment and on-treatment blood samples assessed CPI-induced shifts in B- and T-cell phenotypes, and baseline signatures were used as predictive biomarkers. Results Circulating IL-10+ plasmablasts, double negative (DN), CD21lo B-cell frequencies, and downregulation of key B-cell activation markers (CD21, CXCR5, IL2, CD38) are enriched on B cells from patients with melanoma compared with healthy participants. We observed higher abundance of activated cytotoxic and exhausted (CD8+ PD-1+) and DN (CD4−CD8−) T cells, and higher FoxP3 and transforming growth factor (TGF)β expression by T cells in melanoma. In a patient cohort who received anti-PD1 monotherapy or in combination with anti-LAG3 or anti-CTLA4, we observed a proportional increase in total B-cell frequency, and reduction in memory B cells. We also found expanded activated naïve (CD21hi) B cells and rapidly responding plasmablasts alongside higher expression of B-cell activation markers (CD21, IgD, IgM, CD38, HLA-DR) on the overall B-cell population, suggesting a de novo B-cell response to treatment. Similarly, the T-cell phenotype is altered on treatment favouring activated cytotoxic, immunosuppressive (CD8+ TGFβ+ VEGF+) and exhausted (CD8+ PD-1+) T cells, resting central memory (CD4+) T cells and increased expression of activation markers (CD38, HLA-DR and CD28) by T cells. Baseline enrichment of transitional B cells and plasmablasts, alongside resting CD8+, regulatory (CD4+FoxP3+) and immunosuppressive (VEGF+TGFβ+) T cells were associated with reduced overall survival. Conclusions We report distinct immunosuppressive B- and T-cell signatures in the circulation of patients with melanoma that directly correlate with reduced patient prognosis. Alongside enriched levels of stimulated T cells, we report a de novo B-cell response in patients receiving CPI.
| Reference Key |
openalex_W7165673422
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Lucy Booth, Zena Willsmore, Katie Stoker, Gabriel Osborn, Rebecca Adams, Silvia Crescioli, Yin Wu, Jenny Geh, Thomas Tull, Sophia Tsoka, Sophia Karagiannis |
| Journal | the british journal of dermatology |
| Year | 2026 |
| DOI |
10.1093/bjd/ljag151.034
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.